2024-11-03 08:30:00
Within a few months, the French leader in pharma will be able to produce four vaccines or biomedicines simultaneously. This is what the inauguration, on September 10, of its second factory in Neuville-sur-Saône (Rhône) promises.
A unique factory in the world
The Modulus project required 500 million euros of investment, for 200 jobs.
On 24,000 m², Sanofi designed a factory of 34 independent production modules, reconfigurable in a few days thanks to removable walls and machines, capable of ensuring distinct productions as needed, for a capacity of 500 million doses per year .
This factory for biological products such as vaccines, including mRNA, and treatments such as enzymes and monoclonal antibodies, is unique in the world.
Selected for you
1730656071
#Rhône #Sanofi #armed #unique #factory
**Interview with Dr. Sophie Dubois, Head of Biopharmaceutical Development at Sanofi**
**Interviewer**: Good morning, Dr. Dubois! Thanks for joining us today. With the recent inauguration of the new factory in Neuville-sur-Saône, Sanofi is set to make significant strides in vaccine and biomedicine production. Can you tell us a bit about the innovative features of this facility?
**Dr. Dubois**: Good morning! Thank you for having me. Indeed, the new factory is groundbreaking. It consists of 34 independent production modules that can be reconfigured quickly. This flexibility allows us to adapt our production lines to meet the demand for various vaccines and biomedicines, which is crucial in today’s fast-paced environment.
**Interviewer**: That sounds impressive! What does this capability mean for the future of vaccine production, especially in the context of recent global health challenges?
**Dr. Dubois**: It means that we can respond much more swiftly to emerging health threats. With the capacity to produce up to 500 million doses annually, we can develop and distribute vaccines or treatments as needed, which is essential for public health. The modular design also allows us to invest in cutting-edge technology, including mRNA production, which was vital during the COVID-19 pandemic.
**Interviewer**: You mentioned an investment of 500 million euros. How do you see this reflecting on the job market in the region?
**Dr. Dubois**: This investment is expected to create around 200 new jobs, which will not only contribute to our company’s growth but also stimulate the local economy. We’re committed to bringing high-quality jobs to the area while fostering innovation in biopharmaceuticals.
**Interviewer**: how does Sanofi plan to maintain its leading position in the biopharma industry with this new facility?
**Dr. Dubois**: Our approach combines leveraging advanced technology, investing in talent, and prioritizing collaboration. By uniting science, technology, and our dedicated workforce, we aim to push the boundaries of what’s possible in disease prevention and treatment. The Neuville-sur-Saône factory is just one of the many steps we’re taking to realize these ambitions.
**Interviewer**: Thank you, Dr. Dubois, for sharing these insights. It’s exciting to see such advancements in the biopharma landscape!
**Dr. Dubois**: Thank you! It certainly is a significant time for our industry.
